Clinical Trials List
2026-03-01 - 2030-10-09
Phase III
Not yet recruiting9
Recruiting4
ICD-10I10
Essential (primary) hypertension
ICD-9401.0
Malignant essential hypertension
-
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/09/08
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 葉建寬 無
- 李文煌 無
- 鄭朝允 無
- 張獻元 無
- 陳則瑋 無
- 黃鼎鈞 無
- Po Wei Chen 無
- Po-Sheng Chen 無
- 黃睦翔 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Chern-En Chiang 無
- Wen-Chung Yu 無
- Shih-Hsien Sung 無
- 張俊欽 無
- 張皓智 無
- 郭泠 無
- Tze-Fan Chao 無
- 蔡依霖 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 洪元 無
- Chien-Yi Hsu 無
- Yung-Ta Kao 無
- 陳志維 無
- 詹超舜 無
- 蕭成儀 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 邱淳志 無
- Wen-Rui Hao 無
- 陳俊兆 無
- 楊宗燁 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
150 participants
-
Global
11000 participants
